220 related articles for article (PubMed ID: 31132972)
1. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
[TBL] [Abstract][Full Text] [Related]
2. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
3. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Dharmarajan V; Vought VE; Cosgrove MS
J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
6. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
8. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
[TBL] [Abstract][Full Text] [Related]
9. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
[TBL] [Abstract][Full Text] [Related]
10. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
11. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
12. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32162-75. PubMed ID: 18829457
[TBL] [Abstract][Full Text] [Related]
13. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
[TBL] [Abstract][Full Text] [Related]
15. Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
Shinsky SA; Cosgrove MS
J Biol Chem; 2015 Oct; 290(43):25819-33. PubMed ID: 26324722
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
[TBL] [Abstract][Full Text] [Related]
17. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
18. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
19. A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2011 Feb; 286(5):3359-69. PubMed ID: 21106533
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury.
Zhang C; Guan Y; Zou J; Yang X; Bayliss G; Zhuang S
Cell Death Dis; 2022 Sep; 13(9):770. PubMed ID: 36068197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
